Literature DB >> 19574936

Vaginal symptoms in postmenopausal women: self-reported severity, natural history, and risk factors.

Alison J Huang1, Elya E Moore, Edward J Boyko, Delia Scholes, Feng Lin, Eric Vittinghoff, Stephan D Fihn.   

Abstract

OBJECTIVE: This study aimed to examine factors other than estrogen deficiency influencing the development and persistence of vaginal dryness, itching, and painful sexual intercourse after menopause.
METHODS: We analyzed data from a 2-year, population-based cohort of 1,017 postmenopausal women aged 55 to 75 years. Vaginal symptoms were assessed by interviewer-administered questionnaire, and vaginal swabs were performed to assess vaginal pH and microbial flora at baseline, 12 months, and 24 months. Generalized estimating equations were used to identify characteristics associated with symptoms.
RESULTS: Half of the women (n = 471) reported problematic vaginal dryness, a third (n = 316) reported itching, and 40% of sexually active women (n = 166) reported painful intercourse at baseline. Of women not taking estrogen, half of those reporting baseline symptoms were symptomatic after 24 months. Vaginal dryness was associated with younger age (odds ratio [OR], 0.81; 95% CI, 0.69-0.94, per 5-y increase), nonwhite race (ie, African American, Hispanic, Asian or Pacific Islander, or American Indian [OR, 1.53; 95% CI, 1.04-2.27]), diabetes (OR, 1.51; 95% CI, 1.07-2.12), lower 36-item Short-Form Health Survey physical functioning scores (OR, 0.90; 95% CI, 0.85-0.97, per 10-point increase), lower body mass index (OR, 0.81; 95% CI, 0.71-0.93, per 5 kg/m increase), recent sexual activity (OR, 1.14; 95% CI, 1.08-1.21), and vaginal colonization with enterococci (OR, 1.25; 95% CI, 1.04-1.51). Vaginal itching was also associated with lower physical functioning scores (OR, 0.86; 95% CI, 0.80-0.92, per 10-point increase). Risk factors for painful intercourse included younger age (OR, 0.72; 95% CI, 0.56-0.93, per 5-y increase), diabetes (OR, 3.48; 95% CI, 1.93-6.27), lower body mass index (OR, 0.76; 95% CI, 0.61-0.95, per 5 kg/m increase), and higher vaginal pH (OR, 1.10; 95% CI, 1.00-1.21, per 0.5 units).
CONCLUSIONS: Vaginal symptoms affect a large proportion of postmenopausal women, particularly those with diabetes and those with lower body mass index, but may resolve for up to half of women without estrogen therapy.

Entities:  

Mesh:

Year:  2010        PMID: 19574936      PMCID: PMC2806500          DOI: 10.1097/gme.0b013e3181acb9ed

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  20 in total

1.  Genitourinary symptoms in the menopausal transition.

Authors:  Bradley J Van Voorhis
Journal:  Am J Med       Date:  2005-12-19       Impact factor: 4.965

2.  Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives.

Authors:  Nancy Fugate Woods; Ellen Sullivan Mitchell
Journal:  Am J Med       Date:  2005-12-19       Impact factor: 4.965

3.  Effects of estrogen on proton secretion via the apical membrane in vaginal-ectocervical epithelial cells of postmenopausal women.

Authors:  George I Gorodeski
Journal:  Menopause       Date:  2005-11-08       Impact factor: 2.953

4.  SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Number 145, May 2004.

Authors: 
Journal:  Int J Gynaecol Obstet       Date:  2005-02       Impact factor: 3.561

5.  Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative.

Authors:  Lisa M Pastore; Rachel A Carter; Barbara S Hulka; Ellen Wells
Journal:  Maturitas       Date:  2004-12-10       Impact factor: 4.342

6.  The normal vaginal flora, H2O2-producing lactobacilli, and bacterial vaginosis in pregnant women.

Authors:  S L Hillier; M A Krohn; L K Rabe; S J Klebanoff; D A Eschenbach
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

7.  Dyspareunia in Puerto Rican middle-aged women.

Authors:  Yaniris R Avellanet; Ana Patricia Ortiz; José R Pando; Josefina Romaguera
Journal:  Menopause       Date:  2009 Jul-Aug       Impact factor: 2.953

8.  Persistent hot flushes in older postmenopausal women.

Authors:  Alison J Huang; Deborah Grady; Vanessa L Jacoby; Terri L Blackwell; Douglas C Bauer; George F Sawaya
Journal:  Arch Intern Med       Date:  2008-04-28

9.  Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee.

Authors:  L Cardozo; G Bachmann; D McClish; D Fonda; L Birgerson
Journal:  Obstet Gynecol       Date:  1998-10       Impact factor: 7.661

10.  Prevalence of genitourinary and other climacteric symptoms in 61-year-old women.

Authors:  A Stenberg; G Heimer; U Ulmsten; S Cnattingius
Journal:  Maturitas       Date:  1996-05       Impact factor: 4.342

View more
  15 in total

1.  Sisters Peer Counseling in Reproductive Issues After Treatment (SPIRIT): a peer counseling program to improve reproductive health among African American breast cancer survivors.

Authors:  Leslie R Schover; Michelle M Rhodes; George Baum; Jennifer Harned Adams; Rosell Jenkins; Pamela Lewis; Karen Eubanks Jackson
Journal:  Cancer       Date:  2011-04-14       Impact factor: 6.860

2.  Day-to-Day Impact of Vaginal Aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women.

Authors:  Alison J Huang; Steven E Gregorich; Miriam Kuppermann; Sanae Nakagawa; Stephen K Van Den Eeden; Jeanette S Brown; Holly E Richter; Louise C Walter; David Thom; Anita L Stewart
Journal:  Menopause       Date:  2015-02       Impact factor: 2.953

3.  Predictors of impact of vaginal symptoms in postmenopausal women.

Authors:  Mary M Hunter; Sanae Nakagawa; Stephen K Van Den Eeden; Miriam Kuppermann; Alison J Huang
Journal:  Menopause       Date:  2016-01       Impact factor: 2.953

4.  Time to advocate for better science, and better treatments for women.

Authors:  Caroline M Mitchell; Susan D Reed; Katherine A Guthrie
Journal:  Menopause       Date:  2018-10       Impact factor: 2.953

5.  Prevalence and correlates of vaginal estrogenization in postmenopausal women in the United States.

Authors:  Stacy Tessler Lindau; Annie Dude; Natalia Gavrilova; Joscelyn N Hoffmann; L Philip Schumm; Martha K McClintock
Journal:  Menopause       Date:  2017-05       Impact factor: 2.953

Review 6.  Putative functions of tissue kallikrein-related peptidases in vaginal fluid.

Authors:  Carla M J Muytjens; Stella K Vasiliou; Katerina Oikonomopoulou; Ioannis Prassas; Eleftherios P Diamandis
Journal:  Nat Rev Urol       Date:  2016-09-07       Impact factor: 14.432

Review 7.  Pelvic organ prolapse and sexual function.

Authors:  Brigitte Fatton; Renaud de Tayrac; Vincent Letouzey; Stéphanie Huberlant
Journal:  Nat Rev Urol       Date:  2020-06-17       Impact factor: 14.432

8.  Association between postmenopausal vulvovaginal discomfort, vaginal microbiota, and mucosal inflammation.

Authors:  Caroline M Mitchell; Nanxun Ma; Alissa J Mitchell; Michael C Wu; D J Valint; Sean Proll; Susan D Reed; Katherine A Guthrie; Andrea Z Lacroix; Joseph C Larson; Robert Pepin; Daniel Raftery; David N Fredricks; Sujatha Srinivasan
Journal:  Am J Obstet Gynecol       Date:  2021-03-04       Impact factor: 10.693

9.  Patient-centered change in the day-to-day impact of postmenopausal vaginal symptoms: results from a multicenter randomized trial.

Authors:  Carolyn J Gibson; Alison J Huang; Joseph C Larson; Caroline Mitchell; Susan Diem; Andrea LaCroix; Katherine M Newton; Susan D Reed; Katherine A Guthrie
Journal:  Am J Obstet Gynecol       Date:  2020-01-15       Impact factor: 8.661

10.  Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial.

Authors:  Sujal M Parikh; Ekwaro A Obuku; Sarah A Walker; Aggrey S Semeere; Brandon J Auerbach; James G Hakim; Harriet Mayanja-Kizza; Peter N Mugyenyi; Robert A Salata; Cissy M Kityo
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.